(−)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes

The effect of (−)-deprenyl (selegiline), a therapeutic agent for Parkinson’s disease, on the tyramine-induced release of catecholamine from rat brain synaptosomes was studied using a superfusion system. Tyramine (10−7 to 10−5 M) enhanced the release of [3H]noradrenaline (NA) and [3H]dopamine (DA) from forebrain and striatal synaptosomes in a dose-dependent manner. (−)-Deprenyl (5×10−5 M) had no effect on spontaneous catecholamine release, suggesting that it has no tyramine-like catecholamine releasing effect. Pretreatment with (−)- or (+)-deprenyl (5×10−5 M) significantly prevented the tyramine (10−6 M)-induced NA release, but not DA release. The inhibitory action of (−)-deprenyl was not observed on potassium (15 mM)-induced NA release. (−)-Desmethyldeprenyl (5×10−5 M), a metabolite of (−)-deprenyl, and a monoamine oxidase-A (MAO-A) inhibitor, clorgyline (5×10−5 M), failed to block the tyramine-induced NA and DA release. Although (+)-deprenyl, a potent DA uptake inhibitor, did not inhibit tyramine-induced DA release, a catecholamine uptake inhibitor nomifensine (5×10−5 M) did. In summary, (−)-deprenyl at a dose inhibiting tyramine-induced NA release did not have any effect on tyramine-induced DA release or potassium-induced NA release. [Copyright &y& Elsevier]

Copyright of Pharmacological Research is the property of Academic Press Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)